Hester Biosciences Ltd (HESTERBIO) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company described the past year as a significant phase of consolidation, operational strengthening, and capacity building, which has resulted in visible improvements in execution, profitability, and strategic positioning.
- On a consolidated basis, the company reported strong Q4 performance with revenue growth of 22% and a substantial increase in Profit After Tax (PAT), which nearly doubled for the full financial year.
- The Poultry Healthcare division was the primary growth driver, delivering a robust performance with a 41% revenue increase in Q4 and 21% for the full year, supported by deeper market penetration and sustained demand for its vaccine portfolio.
- In contrast, the Animal Healthcare division experienced challenges due to timing-related delays in tender-led immunization programs, which impacted its overall performance for the year, although execution began to improve in Q4.
- The company has successfully capitalized its new fill-finish and BSL-3 facilities, significantly enhancing its product capacity and providing flexibility for future scale-up across domestic and export markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.